Internal and Emergency Medicine

, 6:17

Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease

Authors

    • First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche intestinali, Fondazione IRCCS Policlinico S. MatteoUniversity of Pavia
    • Clinica Medica I, Fondazione IRCCS Policlinico San Matteo
  • Lucio Liberato
    • First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche intestinali, Fondazione IRCCS Policlinico S. MatteoUniversity of Pavia
  • Monia Marchetti
    • First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche intestinali, Fondazione IRCCS Policlinico S. MatteoUniversity of Pavia
  • Paolo Biancheri
    • First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche intestinali, Fondazione IRCCS Policlinico S. MatteoUniversity of Pavia
  • Gino R. Corazza
    • First Department of Medicine, Centro per lo Studio e la Cura delle Malattie Infiammatorie Croniche intestinali, Fondazione IRCCS Policlinico S. MatteoUniversity of Pavia
SYMPOSIUM – BIOLOGICAL THERAPIES: NEW INDICATIONS, CLINICAL AND PHARMACO-ECONOMIC ASSESSMENT

DOI: 10.1007/s11739-011-0673-9

Cite this article as:
Di Sabatino, A., Liberato, L., Marchetti, M. et al. Intern Emerg Med (2011) 6: 17. doi:10.1007/s11739-011-0673-9

Abstract

Inflammatory bowel diseases (IBD), namely Crohn’s disease and ulcerative colitis, are burdened by high medical costs which are mostly dependent on hospital inpatient treatment. New biologic therapies, which target specific cytokines in the inflammatory cascade leading to the intestinal lesions, including tumor necrosis factor (TNF)-α, have revolutionized the management of IBD by offering a therapeutic chance to patients in whom conventional therapies failed. However, the relatively high costs of biologic drugs, together with their potential toxicity due to infections and malignancies, have led to debate regarding their indiscriminate use in IBD patients. The purpose of this review is to deal with the optimal use and cost-effectiveness of the two main monoclonal anti-TNF-α agents currently used in the management of IBD patients, i.e. the chimeric human/murine antibody infliximab and the fully human antibody adalimumab.

Keywords

AdalimumabHospitalizationInfliximabMucosal healingSurgeryTop-down

Abbreviations

ATI

Anti-drug antibodies

CD

Crohn’s disease

CRP

C-reactive protein

IBD

Inflammatory bowel disease

QALY

Quality-adjusted life years

TNF

Tumor necrosis factor

UC

Ulcerative colitis

Copyright information

© SIMI 2011